BVT Knock-Out MRK/ DE000VZ5YXP2 /
2024-04-26 10:21:08 AM | Chg.+0.050 | Bid12:45:53 PM | Ask12:45:53 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
7.440EUR | +0.68% | 7.540 Bid Size: 14,000 |
7.550 Ask Size: 14,000 |
MERCK KGAA O.N. | 76.62 EUR | 2078-12-31 | Call |
GlobeNewswire
04-25
Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes ...
GlobeNewswire
03-04
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Ger...
GlobeNewswire
2023-12-21
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
2023-12-14
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development an...
GlobeNewswire
2023-10-17
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA